Clinical trial

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

NCT02025010

Study summary

ClinicalTrials.gov

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record abiraterone acetate Normalized identity: abiraterone acetate View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-01-27

PhasePHASE2

Conditions

Castration-resistant Prostate Cancerunresolved

Interventions

abiraterone acetateDRUG · verified · RxNorm: abiraterone acetate

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Janssen Research & Development, LLCcollaborator

Mapped research locations

BostonMassachusetts, United States2 New YorkNew York, United States1 CommackNew York, United States1 Basking RidgeNew Jersey, United States1 HarrisonNew York, United States1 Rockville CentreNew York, United States1 Sleepy HollowNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02025010 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.